<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769482</url>
  </required_header>
  <id_info>
    <org_study_id>2011-07-048</org_study_id>
    <nct_id>NCT01769482</nct_id>
  </id_info>
  <brief_title>Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image</brief_title>
  <acronym>UMPIRE</acronym>
  <official_title>Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current therapeutic options for a well-recognized group of patients with anginal symptoms-a&#xD;
      positive exercise tolerance testing, SPECT or perfusion defect in MRI but angiographically&#xD;
      normal coronary arteries-are limited. The condition, referred to as microvascular angina&#xD;
      (MVA) or cardiac syndrome X, is not as benign as originally reported-patients presenting with&#xD;
      unstable angina and nonobstructive atherosclerotic coronary artery disease have a 2% risk of&#xD;
      death or myocardial infarction at 30 days of follow-up. It is more common in women in whom&#xD;
      the first presentation of angina occurs either perimenopausally or postmenopausally. Aberrant&#xD;
      flow-mediated coronary vasomotion is pivotal in the pathogenesis (systemic) impairment in&#xD;
      endothelial function. Indeed, some centers use systemic assessments of vascular function in&#xD;
      their diagnostic pathways for this group of women. It was recently suggested that endothelial&#xD;
      dysfunction may lead to myocardial ischemia.&#xD;
&#xD;
      In the present study, the investigators tested the hypothesis that udenafil offers dual&#xD;
      benefits of improving vascular function and lessening ischemia in women with angina,&#xD;
      perfusion defect in cardiac MRI, and normal coronary arteries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is that udenafil offers dual benefits of improving vascular function&#xD;
      and lessening ischemia in women with microvascular angina, perfusion defect in cardiac MRI,&#xD;
      and normal coronary arteries.&#xD;
&#xD;
      The UMPIRE trial is a multi-center, prospective, randomized, placebo controlled trial,&#xD;
      designed to evaluate the effect of udenafil in improvement of myocardial stress perfusion&#xD;
      defect in cardiac MRI, in women patients with microvascular angina. A total of 70 patients&#xD;
      will be randomized to udenafil(100 mg q d) or placebo treatment. The primary end point of the&#xD;
      study is Change of perfusion defect over 25% of baseline defect in adenosine-stress cardiac&#xD;
      MRI after 3-month treatment. The secondary endpoints of this study are change of perfusion&#xD;
      defect less than 25% of baseline defect in adenosine-stress cardiac MRI after 3-month&#xD;
      treatment, decrement of frequency of chest pain, improvement of ST-depression in stress test,&#xD;
      improvement of duke score in stress test, improvement of QoL assessment by SF-36&#xD;
      questionnaire, improvement of sexual dysfunction assessment by BISF-W self-questionnaire and&#xD;
      improvement of biomarkers foe endothelial function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to change of perfusion defect over 25% of baseline defect in adenosine-stress cardiac MRI after 3-month treatment.</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to change of perfusion defect less than 25% of baseline defect in adenosine-stress cardiac MRI after 3-month treatment</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>to change of frequency of chest pain</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>to change of improvement of ST-depression in ECG</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>to change of QoL(Quality of Life)</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>to change of sexual dysfunction</measure>
    <time_frame>baseline, 3 months after treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>to change of improvement of biomarkers for endothelial function</measure>
    <time_frame>baseline and 3 months after treatment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Microvascular Angina</condition>
  <arm_group>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.</description>
    <arm_group_label>Udenafil</arm_group_label>
    <other_name>Zydena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. MVA patients with typical symptom and positive adenosine-stress cardiac MRI and with&#xD;
             normal coronary artery in coronary angiogram or coronary artery CT angiography.&#xD;
&#xD;
          2. Definition of positive adenosine-stress MRI: perfusion defect &gt; 25% of transmurality (&#xD;
             by 2 radiologist based on visual assessment and qualitative assessment in core-lab)&#xD;
&#xD;
          3. Gender: female&#xD;
&#xD;
          4. Age: 18-80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient with contraindication to MR contrast media or MR Imaging&#xD;
&#xD;
          2. LVEF &lt; 50%&#xD;
&#xD;
          3. Any heart rhythm abnormality other than sinus rhythm&#xD;
&#xD;
          4. Valvular heart disease with more than moderate degree&#xD;
&#xD;
          5. Renal failure&#xD;
&#xD;
          6. Congestive Heart Failure&#xD;
&#xD;
          7. Myocardial infraction&#xD;
&#xD;
          8. Myocarditis&#xD;
&#xD;
          9. Congenital heart disease&#xD;
&#xD;
         10. Pericarditis&#xD;
&#xD;
         11. Variant angina (positive provocation test with Ergonovine or acetylcholine)&#xD;
&#xD;
         12. GERD (conformed by esophagogastroduodenoscopy)&#xD;
&#xD;
         13. Pregnant women with suspected, pregnant women or women with lactation&#xD;
&#xD;
         14. QT prolongation syndrome or take drugs that prolong the QT interval - Antiarrhythmics&#xD;
             class IA; quinidine, procainamide - Antiarrhythmics class III; amiodarone, sotalol&#xD;
&#xD;
         15. Preanalytical within 30 days of screening in a clinical trial that may affect the&#xD;
             influence of udenafil&#xD;
&#xD;
             - Other PDE5 inhibitors (ex. Sildenafil, tadalafil)&#xD;
&#xD;
             - Nitrates/ NO donor (ex. Nitroglycerin, isosorbide mononitrate, isosorbide dinitrate,&#xD;
             amyl nitrate/nitrite, sodium nitroprusside, nicorandil)&#xD;
&#xD;
         16. Preanalytical within 7 days of screening in a clinical trial that may affect the&#xD;
             metabolism of udenafil&#xD;
&#xD;
               -  Antibacterials (ex. Erythromycin)&#xD;
&#xD;
               -  Antifungals (ex. Itraconazole, ketoconazole)&#xD;
&#xD;
               -  Antivirals (ex. Ritonavir, saquinavir, amprenavir, indinavir, nelfinavir)&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
         17. Allergy or sensitivity with PDE 5 inhibitors&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Ji Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Ji Park, M.D.,Ph.D.</last_name>
    <phone>82-2-3410-0887</phone>
    <email>tyche.park@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Ju Choi, M.D.,Ph.D.</last_name>
      <phone>82-31-787-7007</phone>
      <email>djchoi@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Ju Choi, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eng-Ju Kim, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Eng-Ju Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microvascular angina</keyword>
  <keyword>PDE-5 inhibitors</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

